{"gene":"NLRC5","run_date":"2026-04-29T11:37:57","timeline":{"discoveries":[{"year":2010,"finding":"NLRC5 inhibits NF-κB-dependent responses by directly interacting with IKKα and IKKβ and blocking their phosphorylation, and also interacts with RIG-I and MDA5 (but not MAVS) to inhibit RLR-mediated type I interferon responses.","method":"Co-immunoprecipitation, siRNA knockdown with NF-κB/IFN reporter assays, phosphorylation assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP plus functional knockdown phenotype, replicated in multiple cell types","pmids":["20434986"],"is_preprint":false},{"year":2010,"finding":"NLRC5 is an IFN-γ-inducible nuclear protein that acts as a transcriptional regulator (class I transactivator, CITA) of MHC class I genes; it associates with MHC class I gene promoters and is required for IFN-γ-induced upregulation of MHC class I, β2-microglobulin, TAP1, and LMP2.","method":"Chromatin immunoprecipitation (ChIP), reporter gene assays, siRNA knockdown, overexpression in lymphoid and epithelial cell lines","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — ChIP plus reporter assays plus KD phenotype, replicated across multiple studies","pmids":["20639463"],"is_preprint":false},{"year":2010,"finding":"NLRC5 shuttles between the cytosol and the nucleus in a CrmA-dependent manner, and overexpression globally dampens NF-κB-, AP-1-, and type I IFN-dependent signaling, most likely through transcriptional repression.","method":"Subcellular fractionation/localization, overexpression in HEK293T cells, reporter assays, siRNA knockdown in RAW264.7 macrophages","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2-3 — localization with functional consequence shown, single lab","pmids":["20610642"],"is_preprint":false},{"year":2010,"finding":"NLRC5 forms an inflammasome complex: it biochemically associates with NLRP3 in a nucleotide-binding domain-dependent but LRR-inhibitory fashion, and together with procaspase-1, pro-IL-1β, and ASC reconstitutes inflammasome activity cooperative with NLRP3; RNAi knockdown nearly eliminated caspase-1, IL-1β, and IL-18 processing.","method":"Co-immunoprecipitation, reconstitution assay, siRNA knockdown in primary human monocytic cells","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — biochemical reconstitution plus Co-IP, but later knockout studies showed partial or no confirmation","pmids":["21191067"],"is_preprint":false},{"year":2010,"finding":"Overexpression and enforced oligomerization of NLRC5 activates IFN-γ activation sequence (GAS) and IFN-specific response element (ISRE) promoter elements and upregulates antiviral target genes; JAK/STAT-mediated autocrine IFN-γ signaling loop is involved in NLRC5 upregulation post-CMV infection.","method":"Reporter gene assays (GAS/ISRE), siRNA knockdown, overexpression with forced oligomerization","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2-3 — reporter assays with functional knockdown, single lab","pmids":["20061403"],"is_preprint":false},{"year":2012,"finding":"NLRC5 deficiency in mice results in a profound defect specifically in MHC class I expression (and related genes β2M, TAP1, LMP2) in T, NKT, and NK lymphocytes but only mildly affects APCs; endogenous NLRC5 localizes to the nucleus and occupies proximal promoter regions of H-2 genes; MHC class I induction requires both CARD and LRR domains.","method":"Nlrc5-knockout mouse generation, flow cytometry, nuclear fractionation, ChIP","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods in KO mice, replicated by independent labs","pmids":["22412192"],"is_preprint":false},{"year":2012,"finding":"In NLRC5-deficient mice, MHC class I expression and genes essential for antigen presentation (H-2K, H-2D, β2M, TAP1, LMP2) are severely reduced; IFN-γ stimulation cannot overcome this defect; Listeria-specific CD8+ T cell responses are impaired and bacterial clearance is reduced.","method":"NLRC5 knockout mouse, flow cytometry, bacterial infection model, CD8+ T cell functional assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — independent KO mouse study confirming MHC-I transactivation role with in vivo functional readout","pmids":["22711889"],"is_preprint":false},{"year":2012,"finding":"NLRC5-deficient mice show enhanced IKK and IRF3 phosphorylation and increased IL-6 and IFN-β production in response to TLR stimulation or VSV infection; NLRC5 expression induction by TLR ligands or cytokines requires STAT1-mediated signaling.","method":"NLRC5 knockout mouse, phosphorylation assays (IKK, IRF3), ELISA for cytokines, STAT1 pathway analysis","journal":"Cell research","confidence":"High","confidence_rationale":"Tier 2 — in vivo KO mouse with multiple biochemical readouts","pmids":["22473004"],"is_preprint":false},{"year":2012,"finding":"NLRC5 is required for MHC class I-mediated antigen presentation in vivo; NLRC5-deficient mice show profound defect in MHC class I gene expression, fail to activate Listeria-specific CD8+ T cell responses, and show partial impairment of NLRP3-mediated inflammasome activation, but NLRC5 is dispensable for NF-κB-dependent pro-inflammatory gene expression and type I IFN genes.","method":"NLRC5 knockout mouse, flow cytometry, CD8+ T cell activation/proliferation/cytotoxicity assays, bacterial infection","journal":"Cell research","confidence":"High","confidence_rationale":"Tier 2 — independent KO mouse study with comprehensive in vivo analysis","pmids":["22491475"],"is_preprint":false},{"year":2012,"finding":"The nucleotide-binding domain (NBD) of NLRC5 is critical for both nuclear translocation and transactivation of MHC class I genes; intact nuclear localization signal is required for NLRC5-mediated MHC class I gene induction.","method":"NBD domain mutants, nuclear localization signal mutagenesis, reporter gene assays, cellular localization studies","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — domain mutagenesis with functional reporter assays, single lab","pmids":["22310711"],"is_preprint":false},{"year":2014,"finding":"The N-terminal effector domain of NLRC5 adopts a six α-helix bundle with a general death fold (atypical CARD), structurally distinct from canonical CARD; in vitro interaction experiments with the tandem CARD of RIG-I were performed; the atypical features affect the electrostatic surface and likely modulate CARD-CARD interactions.","method":"Solution NMR structure determination, in vitro pulldown/interaction experiments","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — NMR structure with in vitro interaction validation","pmids":["24815518"],"is_preprint":false},{"year":2014,"finding":"NLRC5 binds RIG-I via its N-terminal death domain; this interaction is critical for robust antiviral responses against influenza virus; NLRC5 extends and stabilizes influenza virus-induced RIG-I expression; influenza NS1 protein binds NLRC5 to suppress its function; antiviral activity is LRR domain-independent.","method":"Co-immunoprecipitation, domain mapping, overexpression/knockdown in A549 and primary bronchial cells, viral replication assays","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP with domain mapping, single lab","pmids":["25404059"],"is_preprint":false},{"year":2015,"finding":"NLRC5 exclusively transactivates MHC class I and related non-classical MHCI genes through an SXY enhancer module; recruitment of NLRC5 to MHC class I promoters absolutely requires the enhanceosome factor RFX5; NLRC5 and CIITA occupy distinct SXY motifs with the S box being the key determinant of NLRC5 specificity; Rfx5-knockout mice phenocopy Nlrc5 deficiency for MHCI expression.","method":"ChIP-sequencing, Rfx5-knockout mice, double-deficient Nlrc5/CIIta mice, de novo motif discovery, reporter assays in B cell lines lacking RFX5/RFXAP/RFXANK","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP-seq plus multiple KO mouse models plus reporter assays, comprehensive mechanistic study","pmids":["25811463"],"is_preprint":false},{"year":2015,"finding":"NLRC5 undergoes K63-linked ubiquitination at lysine 1178 by TRAF2/6 after LPS treatment, which leads to dissociation of the NLRC5-IκB kinase complex and creates a coherent feedforward loop to sensitize NF-κB activation; USP14 specifically removes polyubiquitin chains from NLRC5 to restore NLRC5-mediated inhibition of NF-κB signaling.","method":"Ubiquitination assay, site-directed mutagenesis (K1178), Co-IP, mathematical modeling, USP14 deubiquitinase identification","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1-2 — mutagenesis identifying ubiquitination site, identification of writer (TRAF2/6) and eraser (USP14), plus mathematical modeling","pmids":["26620909"],"is_preprint":false},{"year":2016,"finding":"NLRC5 shields T lymphocytes from NK-cell-mediated killing under inflammatory conditions by maintaining high MHCI expression; T-cell-specific Nlrc5-deficient mice show NK cells breaking tolerance toward self Nlrc5-deficient T cells under inflammation; during chronic LCMV infection, total CD8+ T cell population is severely decreased in a NK-cell-dependent manner.","method":"T-cell-specific Nlrc5-knockout mice, NK cell depletion, LCMV infection model, flow cytometry","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — conditional KO mouse with NK depletion rescue, multiple orthogonal readouts","pmids":["26861112"],"is_preprint":false},{"year":2021,"finding":"SARS-CoV-2 ORF6 protein suppresses NLRC5 both transcriptionally (by hampering IFN-γ-mediated STAT1 signaling, reducing NLRC5 and IRF1 gene expression) and functionally (by blocking karyopherin complex-dependent nuclear import of NLRC5), thereby inhibiting MHC class I pathway induction.","method":"Gene expression profiling of COVID-19 patients and infected cell lines, ORF6 overexpression, nuclear import assays, STAT1 signaling analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods identifying transcriptional and post-translational suppression mechanism with patient-derived data","pmids":["34782627"],"is_preprint":false},{"year":2020,"finding":"NLRC5 promotes transcription of BTN3A1-3 genes through an atypical regulatory motif in their promoters; forcing NLRC5 expression promotes Vγ9Vδ2 T-cell-mediated killing of tumor cells in a BTN3A-dependent manner.","method":"ChIP, reporter assays, NLRC5 overexpression, co-culture killing assays with BTN3A neutralization","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP plus functional killing assay with BTN3A dependency shown, single lab","pmids":["33364588"],"is_preprint":false},{"year":2022,"finding":"NLRC5 interacts with dengue virus NS3 protease domain and mediates its degradation through a ubiquitin-dependent selective autophagy pathway; NLRC5 recruits E3 ubiquitin ligase CUL2 to catalyze K48-linked poly-ubiquitination of NS3, which serves as a recognition signal for TOLLIP-mediated selective autophagic degradation.","method":"Co-immunoprecipitation, ubiquitination assays, autophagy pathway analysis, NLRC5 knockout/overexpression, viral replication assays","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP plus ubiquitination site identification plus autophagic degradation pathway, single lab","pmids":["36126167"],"is_preprint":false},{"year":2024,"finding":"NLRC5 acts as an innate immune sensor for NAD+ depletion and specific PAMP/heme and heme/cytokine combinations to drive PANoptosis (inflammatory cell death); NLRC5 interacts with NLRP12 and PANoptosome components to form a multi-protein cell death complex; TLR signaling and NAD+ levels regulate NLRC5 expression and ROS production to control cell death; NLRC5-deficient mice are protected in hemolytic and inflammatory models.","method":"PANoptosis screening, Co-immunoprecipitation with NLRP12 and PANoptosome components, NLRC5-deficient mice, cell death assays, ROS measurement","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — Co-IP with multiple partners, KO mouse in vivo models, multiple orthogonal cell death readouts","pmids":["38878777"],"is_preprint":false},{"year":2022,"finding":"In human pancreatic β cells, NLRC5 is induced by IFNα and regulates HLA class I expression, antigen presentation-related genes, chemokines, and mediates IFNα effects on alternative splicing that generates neoantigens.","method":"Bulk and single-cell RNA sequencing, NLRC5 knockdown in EndoC-βH1 and human islet cells, targeted gene/protein determination","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 — RNA-seq plus targeted KD with functional readouts, single lab","pmids":["36103539"],"is_preprint":false},{"year":2020,"finding":"PRMT5 inhibits transcription of the NLRC5 gene; PRMT5 knockdown augments NLRC5 expression and increases MHC class I abundance in melanoma cells; combining PRMT5 inhibition with immune checkpoint therapy enhanced antitumor efficacy.","method":"PRMT5 knockdown/inhibition, gene expression analysis, MHC-I flow cytometry, in vivo tumor models","journal":"Science translational medicine","confidence":"Medium","confidence_rationale":"Tier 2-3 — functional KD with expression and in vivo readouts, PRMT5 identified as upstream transcriptional repressor","pmids":["32641491"],"is_preprint":false},{"year":2021,"finding":"Autophagy protein LC3 directly interacts with NLRC5 and inhibits NLRC5-mediated MHC class I antigen presentation pathway in vitro and in vivo; negative correlation between NLRC5 and LC3 levels was found in endometrial cancer.","method":"Co-immunoprecipitation (LC3-NLRC5), overexpression/knockdown, in vivo tumor model, MHC-I expression assays","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP plus in vivo validation, single lab","pmids":["34974132"],"is_preprint":false},{"year":2023,"finding":"METTL3 facilitates m6A modification of NLRC5 mRNA; YTHDF2 promotes degradation of NLRC5 mRNA; METTL3 inhibits NLRC5 mRNA degradation through a YTHDF2-dependent mechanism, thereby promoting MHC-I-mediated immunosurveillance in endometrial cancer.","method":"RNA immunoprecipitation (RIP), methylated RIP, RNA stability assays, METTL3/YTHDF2 overexpression/depletion, in vivo tumor model","journal":"Biomarker research","confidence":"Medium","confidence_rationale":"Tier 2 — RIP plus methylated RIP plus RNA stability assays identifying m6A writer and reader, single lab","pmids":["37085864"],"is_preprint":false},{"year":2022,"finding":"USP14 deubiquitinase directly interacts with NLRC5 and suppresses its degradation, thereby upregulating NLRC5-mediated inhibition of NF-κB signaling in endothelial cells to restrain atherosclerosis progression.","method":"Co-immunoprecipitation, ubiquitination assay, USP14 overexpression/knockdown, in vivo ApoE-/- mouse model","journal":"Biochimica et biophysica acta. Molecular and cell biology of lipids","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP and functional KD/OE with in vivo model, single lab","pmids":["36372300"],"is_preprint":false},{"year":2023,"finding":"USP14 promotes deubiquitination and upregulation of NLRC5, with subsequent Smad2/3 pathway activation to drive endothelial-to-mesenchymal transformation (EndMT) in atherosclerosis; USF1 transcriptionally activates USP14, forming a USF1/USP14/NLRC5 axis.","method":"Dual-luciferase reporter assay, ChIP, Co-IP, USF1/USP14/NLRC5 knockdown/overexpression, in vivo ApoE-/- mouse model","journal":"Molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP, Co-IP, reporter assays, and in vivo confirmation, single lab","pmids":["38424494"],"is_preprint":false},{"year":2023,"finding":"NLRC5 deficiency in macrophages decreases NF-κB pathway activation and reduces secretion of IL-6; mechanistically, NLRC5 interacts with HSPA8 (heat shock cognate protein 70) to suppress NF-κB signaling; myeloid-specific NLRC5 deletion aggravates pressure overload-induced cardiac remodeling.","method":"Myeloid-specific NLRC5 knockout mice, Co-immunoprecipitation (NLRC5-HSPA8), NF-κB signaling assays, cytokine measurement, cardiac remodeling model","journal":"JACC. Basic to translational science","confidence":"Medium","confidence_rationale":"Tier 2 — conditional KO plus Co-IP identifying HSPA8 as binding partner, single lab","pmids":["37325412"],"is_preprint":false},{"year":2019,"finding":"In HIV-1 Tat-exposed microglia, miRNA-34a is upregulated and directly targets NLRC5 mRNA (identified by bioinformatics and Argonaute immunoprecipitation); downregulation of NLRC5 by miR-34a leads to increased NF-κB p65 expression and microglial inflammation.","method":"Argonaute immunoprecipitation, miR-34a mimic/inhibitor transfection, NF-κB expression assays, validated in HIV-1 transgenic rat and SIV-infected macaque brain","journal":"Brain, behavior, and immunity","confidence":"Medium","confidence_rationale":"Tier 2-3 — Argonaute IP plus in vivo validation in animal models, single lab","pmids":["30872089"],"is_preprint":false},{"year":2021,"finding":"NLRC5 deficiency in macrophages (myeloid-specific knockout) leads to higher chemokine and cytokine production in response to Helicobacter and promotes B-cell activating factor-driven B-cell hyperproliferation and gastric lymphoid tissue formation.","method":"Myeloid-specific Nlrc5-KO mice (Nlrc5mø-KO), CRISPR-Cas9 NLRC5-/- THP-1 cells, H. felis infection model, cytokine assays, histology","journal":"Gastroenterology","confidence":"Medium","confidence_rationale":"Tier 2 — conditional KO mouse plus CRISPR cell line with in vivo infection model, single lab","pmids":["32169428"],"is_preprint":false},{"year":2021,"finding":"NLRC5 deficiency reduces dopaminergic neurodegeneration in MPTP-induced Parkinson's disease model; NLRC5 deficiency decreased proinflammatory gene expression in microglia and astrocytes by suppressing NF-κB and MAPK signaling pathways and enhancing AKT-GSK-3β and AMPK signaling; in neurons, NLRC5 deficiency promoted NF-κB and AKT signaling and increased survival.","method":"NLRC5-deficient mice, MPTP model, primary microglia/astrocyte cultures, NF-κB/MAPK/AKT signaling assays, dopaminergic neuron counting","journal":"Journal of neuroinflammation","confidence":"Medium","confidence_rationale":"Tier 2 — KO mouse with multiple in vivo and in vitro mechanistic readouts, single lab","pmids":["37072793"],"is_preprint":false},{"year":2021,"finding":"In ischemic retinopathy, NLRC5 directly binds NLRP3 and NLRC4 in inflammasomes to cooperatively drive microglial pyroptosis and apoptosis; NLRC5 knockdown markedly suppressed gasdermin D (GSDMD) cleavage and activation of IL-1β and caspase-3.","method":"Co-immunoprecipitation (NLRC5-NLRP3, NLRC5-NLRC4), NLRC5 knockdown in retinal microglia, GSDMD cleavage assay, retinal ischemia-reperfusion model","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP plus functional KD with defined pyroptosis readout, single lab","pmids":["34095138"],"is_preprint":false}],"current_model":"NLRC5 is primarily established as the master transcriptional co-activator (CITA) of MHC class I genes, recruited to SXY enhancer motifs via the RFX5-containing enhanceosome complex where it drives coordinated expression of MHC-I, β2M, TAP1, and LMP2; it shuttles to the nucleus via a karyopherin-dependent mechanism requiring an intact NBD and NLS; it negatively regulates NF-κB signaling by interacting with and blocking phosphorylation of IKKα/β, with this inhibitory activity dynamically controlled by TRAF2/6-mediated K63-ubiquitination at K1178 and USP14-mediated deubiquitination; it also interacts with RIG-I and MDA5 to modulate antiviral interferon responses; and it can form PANoptosome cell death complexes with NLRP12 and inflammasome components to drive inflammatory cell death in response to NAD+ depletion and specific PAMPs."},"narrative":{"teleology":[{"year":2010,"claim":"The first functional characterization of NLRC5 established two cytoplasmic signaling roles — inhibition of NF-κB via direct IKKα/β binding and suppression of RLR-mediated type I IFN responses via RIG-I/MDA5 interaction — revealing it as a negative regulator of innate immune signaling.","evidence":"Co-immunoprecipitation, phosphorylation assays, and siRNA knockdown with reporter assays in multiple cell types","pmids":["20434986"],"confidence":"High","gaps":["Structural basis for IKK interaction unknown","Relative importance of NF-κB vs IFN inhibition in vivo not resolved","Endogenous stoichiometry of NLRC5-IKK complex not measured"]},{"year":2010,"claim":"Concurrent studies identified NLRC5 as a transcriptional co-activator (CITA) of MHC class I genes, fundamentally redefining NLRC5 from a purely cytoplasmic sensor to a nucleo-cytoplasmic shuttling transcriptional regulator that occupies MHC-I promoters and drives coordinated expression of antigen presentation machinery.","evidence":"ChIP on MHC-I promoters, reporter assays, siRNA knockdown, subcellular fractionation in lymphoid and epithelial lines","pmids":["20639463","20610642"],"confidence":"High","gaps":["How NLRC5 is recruited to MHC-I promoters (cis-element specificity) not yet defined","Whether NLRC5 acts independently or through co-factors unknown"]},{"year":2012,"claim":"Generation of NLRC5-knockout mice validated NLRC5 as the dominant, non-redundant transactivator of MHC class I in lymphocytes, showing that its loss profoundly impairs MHC-I expression, CD8+ T cell priming, and Listeria clearance, while its contribution to NF-κB and type I IFN suppression was confirmed by enhanced IKK/IRF3 phosphorylation in KO macrophages.","evidence":"Multiple independent NLRC5-KO mouse lines, flow cytometry, bacterial infection, CD8+ T cell assays, cytokine/phosphorylation measurements","pmids":["22412192","22711889","22491475","22473004"],"confidence":"High","gaps":["Residual MHC-I expression in APCs implies compensatory mechanisms (likely CIITA) not fully delineated","Whether NLRC5 inflammasome role is physiologically relevant was disputed by KO studies"]},{"year":2012,"claim":"Domain mutagenesis established that the NBD is required for nuclear translocation and the NLS is essential for MHC-I transactivation, linking ATP-binding to the nuclear import mechanism.","evidence":"NBD and NLS mutants assessed by reporter assays and localization studies","pmids":["22310711"],"confidence":"Medium","gaps":["Whether NBD hydrolysis or just binding is required not distinguished","Direct NLS–karyopherin interaction not biochemically mapped"]},{"year":2014,"claim":"Structural determination of the NLRC5 N-terminal domain revealed an atypical CARD (six α-helix death fold) with a modified electrostatic surface, explaining how it engages RIG-I tandem CARDs and contributes to antiviral signaling.","evidence":"Solution NMR structure plus in vitro pulldown with RIG-I CARDs","pmids":["24815518","25404059"],"confidence":"High","gaps":["Full-length NLRC5 structure unavailable","How atypical CARD engages enhanceosome or IKK not resolved"]},{"year":2015,"claim":"ChIP-seq and genetic epistasis defined the mechanism of NLRC5 promoter specificity: NLRC5 is recruited exclusively to SXY enhancer modules via the RFX5 enhanceosome, with the S-box distinguishing NLRC5-dependent MHC-I from CIITA-dependent MHC-II promoters.","evidence":"ChIP-seq, Rfx5-KO and Nlrc5/CIIta double-KO mice, de novo motif analysis, reporter assays in RFX-deficient B cells","pmids":["25811463"],"confidence":"High","gaps":["Precise protein–protein contacts between NLRC5 and RFX5 not structurally resolved","How atypical CARD contributes to enhanceosome assembly unknown"]},{"year":2015,"claim":"A post-translational regulatory circuit was elucidated: TRAF2/6-mediated K63-ubiquitination at K1178 releases NLRC5 from IKK, creating a feedforward loop that sensitizes NF-κB, while USP14 deubiquitinates NLRC5 to restore inhibition — establishing dynamic control of NLRC5's NF-κB-suppressive function.","evidence":"Site-directed mutagenesis (K1178), ubiquitination assays, USP14 identification, mathematical modeling","pmids":["26620909"],"confidence":"High","gaps":["Whether K63-ubiquitination also affects nuclear import or MHC-I transactivation not tested","Other E3 ligases or DUBs that regulate NLRC5 not excluded"]},{"year":2016,"claim":"Conditional T-cell-specific NLRC5 deletion revealed the physiological consequence of NLRC5-driven MHC-I: protection of T cells from NK-cell-mediated killing during inflammation and chronic viral infection, establishing NLRC5 as essential for self-tolerance maintenance.","evidence":"T-cell-specific Nlrc5-KO mice, NK depletion rescue, LCMV infection model","pmids":["26861112"],"confidence":"High","gaps":["Whether NK licensing is altered by NLRC5 deficiency not addressed","Contribution of non-classical MHC-I ligands not separated"]},{"year":2020,"claim":"The transcriptional target repertoire of NLRC5 was expanded beyond classical MHC-I to include BTN3A1-3 butyrophilin genes, linking NLRC5 to γδ T cell-mediated tumor surveillance, and upstream regulation by PRMT5-mediated transcriptional repression of NLRC5 itself was identified.","evidence":"ChIP and reporter assays for BTN3A promoters; PRMT5 knockdown/inhibition with MHC-I and tumor model readouts","pmids":["33364588","32641491"],"confidence":"Medium","gaps":["Whether NLRC5 uses the same SXY/RFX5 mechanism for BTN3A not fully defined","PRMT5 mechanism (direct histone methylation vs indirect) at NLRC5 locus not resolved"]},{"year":2021,"claim":"SARS-CoV-2 ORF6 was shown to suppress NLRC5 at two levels — blocking STAT1-dependent transcription of NLRC5 and inhibiting karyopherin-mediated nuclear import — revealing a viral immune evasion strategy targeting MHC-I transactivation.","evidence":"ORF6 overexpression, nuclear import assays, STAT1 signaling analysis, COVID-19 patient expression data","pmids":["34782627"],"confidence":"High","gaps":["Whether other coronaviruses use the same mechanism unknown","Impact on patient CD8+ T cell responses not directly measured"]},{"year":2022,"claim":"Post-transcriptional regulation of NLRC5 was characterized: m6A modification of NLRC5 mRNA by METTL3 stabilizes it against YTHDF2-mediated decay, and LC3 directly binds NLRC5 protein to inhibit its MHC-I transactivation, adding epitranscriptomic and autophagic layers of control.","evidence":"RNA immunoprecipitation, methylated RIP, RNA stability assays, LC3-NLRC5 Co-IP with in vivo tumor models","pmids":["37085864","34974132"],"confidence":"Medium","gaps":["Whether LC3 sequesters NLRC5 in the cytoplasm or promotes its degradation not distinguished","m6A regulation in non-cancer contexts not examined"]},{"year":2022,"claim":"A new cytoplasmic effector function was identified: NLRC5 recruits the E3 ligase CUL2 to catalyze K48-ubiquitination of dengue virus NS3, targeting it for TOLLIP-mediated selective autophagic degradation, linking NLRC5 to antiviral autophagy independent of its transcriptional role.","evidence":"Co-IP, ubiquitination assays, autophagy pathway analysis, NLRC5 KO/OE with viral replication readouts","pmids":["36126167"],"confidence":"Medium","gaps":["Whether this autophagy-targeting function extends to other viral proteins unknown","Structural basis for NS3 recognition not defined","Single-lab finding awaits independent confirmation"]},{"year":2024,"claim":"NLRC5 was identified as an innate sensor of NAD+ depletion that assembles with NLRP12 and PANoptosome components to drive PANoptosis (combined pyroptosis, apoptosis, and necroptosis), establishing a cell death function distinct from its transcriptional and NF-κB-inhibitory roles.","evidence":"PANoptosis screening, Co-IP with NLRP12 and cell death effectors, NLRC5-KO mice in hemolytic and inflammatory models, ROS measurements","pmids":["38878777"],"confidence":"High","gaps":["How NLRC5 senses NAD+ depletion (direct binding vs indirect) not determined","Structural basis of NLRC5-NLRP12 interaction unknown","Whether PANoptosome function is active in non-myeloid cells not established"]},{"year":null,"claim":"Major open questions include: (1) the structural basis for NLRC5 engagement with the RFX5 enhanceosome versus cytoplasmic signaling partners, (2) how the transcriptional, NF-κB-inhibitory, and PANoptosome functions are partitioned across cell types and stimuli, and (3) whether a unifying activation mechanism (nucleotide binding/hydrolysis) controls toggling between nuclear and cytoplasmic functions.","evidence":"","pmids":[],"confidence":"Low","gaps":["No full-length NLRC5 structure exists","Relative contribution of each function in specific disease contexts not quantified","Allosteric regulation by nucleotide binding/hydrolysis not mechanistically dissected"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,5,6,8,12,16,19]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,7,13,23,25]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,2,5,9,12]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,2,13,18]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,5,6,7,8,11,14,15,18]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,5,12,16,19]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[18,29]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[17]}],"complexes":["RFX5/RFXAP/RFXANK enhanceosome","NLRC5-NLRP12 PANoptosome","NLRC5-IKKα/β inhibitory complex"],"partners":["RFX5","IKKΑ","IKKΒ","NLRP12","RIG-I","USP14","TRAF2","HSPA8"],"other_free_text":[]},"mechanistic_narrative":"NLRC5 is a multifunctional NLR family member that serves as the master transcriptional co-activator (CITA) of MHC class I genes and modulates innate immune signaling and inflammatory cell death. NLRC5 is recruited to SXY enhancer motifs on MHC-I, β2-microglobulin, TAP1, LMP2, and BTN3A promoters through obligate interaction with the RFX5-containing enhanceosome complex, driving coordinated antigen presentation gene expression in an IFN-γ-inducible, karyopherin- and NBD/NLS-dependent manner [PMID:20639463, PMID:25811463, PMID:22412192, PMID:33364588]. In the cytoplasm, NLRC5 inhibits NF-κB signaling by directly binding IKKα/IKKβ and blocking their phosphorylation, with this inhibitory activity dynamically tuned by TRAF2/6-mediated K63-ubiquitination at K1178 and USP14-mediated deubiquitination [PMID:20434986, PMID:26620909, PMID:36372300]. NLRC5 also functions as an innate sensor of NAD+ depletion and specific PAMPs, assembling NLRP12-containing PANoptosome complexes to drive inflammatory cell death, and interacts with RIG-I via its atypical CARD to modulate antiviral interferon responses [PMID:38878777, PMID:20434986, PMID:25404059]."},"prefetch_data":{"uniprot":{"accession":"Q86WI3","full_name":"Protein NLRC5","aliases":["Caterpiller protein 16.1","CLR16.1","Nucleotide-binding oligomerization domain protein 27","Nucleotide-binding oligomerization domain protein 4"],"length_aa":1866,"mass_kda":204.6,"function":"Probable regulator of the NF-kappa-B and type I interferon signaling pathways. May also regulate the type II interferon signaling pathway. Plays a role in homeostatic control of innate immunity and in antiviral defense mechanisms","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q86WI3/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NLRC5","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NLRC5","total_profiled":1310},"omim":[{"mim_id":"613537","title":"NLR FAMILY, CASPASE RECRUITMENT DOMAIN-CONTAINING 5; NLRC5","url":"https://www.omim.org/entry/613537"},{"mim_id":"606636","title":"NLR FAMILY, PYRIN DOMAIN-CONTAINING 1; NLRP1","url":"https://www.omim.org/entry/606636"},{"mim_id":"605980","title":"NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN PROTEIN 1; NOD1","url":"https://www.omim.org/entry/605980"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Centrosome","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":33.8},{"tissue":"lymphoid tissue","ntpm":31.8}],"url":"https://www.proteinatlas.org/search/NLRC5"},"hgnc":{"alias_symbol":["NOD27","CLR16.1","FLJ21709"],"prev_symbol":[]},"alphafold":{"accession":"Q86WI3","domains":[{"cath_id":"1.10.533.20","chopping":"8-81","consensus_level":"high","plddt":70.1526,"start":8,"end":81},{"cath_id":"3.40.50.300","chopping":"144-157_175-188_204-367","consensus_level":"high","plddt":77.1598,"start":144,"end":367},{"cath_id":"3.80.10.10","chopping":"639-782","consensus_level":"medium","plddt":83.4469,"start":639,"end":782},{"cath_id":"3.80.10,3.80.10","chopping":"788-818_845-948_977-998_1005-1079","consensus_level":"medium","plddt":74.9266,"start":788,"end":1079},{"cath_id":"-","chopping":"1111-1191","consensus_level":"medium","plddt":68.7633,"start":1111,"end":1191},{"cath_id":"3.80.10.10","chopping":"1436-1553","consensus_level":"medium","plddt":72.965,"start":1436,"end":1553},{"cath_id":"3.80.10.10","chopping":"1761-1853","consensus_level":"medium","plddt":87.3213,"start":1761,"end":1853},{"cath_id":"1.10.8","chopping":"368-432","consensus_level":"medium","plddt":79.7266,"start":368,"end":432}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q86WI3","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q86WI3-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q86WI3-F1-predicted_aligned_error_v6.png","plddt_mean":73.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NLRC5","jax_strain_url":"https://www.jax.org/strain/search?query=NLRC5"},"sequence":{"accession":"Q86WI3","fasta_url":"https://rest.uniprot.org/uniprotkb/Q86WI3.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q86WI3/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q86WI3"}},"corpus_meta":[{"pmid":"20434986","id":"PMC_20434986","title":"NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/20434986","citation_count":372,"is_preprint":false},{"pmid":"20639463","id":"PMC_20639463","title":"NLR family member NLRC5 is a transcriptional regulator of MHC class I genes.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20639463","citation_count":359,"is_preprint":false},{"pmid":"23175229","id":"PMC_23175229","title":"NLRC5: a key regulator of MHC class I-dependent immune responses.","date":"2012","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23175229","citation_count":306,"is_preprint":false},{"pmid":"27162338","id":"PMC_27162338","title":"NLRC5/MHC class I transactivator is a target for immune evasion in cancer.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27162338","citation_count":222,"is_preprint":false},{"pmid":"20610642","id":"PMC_20610642","title":"NLRC5 limits the activation of inflammatory pathways.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20610642","citation_count":201,"is_preprint":false},{"pmid":"32641491","id":"PMC_32641491","title":"PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity.","date":"2020","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32641491","citation_count":194,"is_preprint":false},{"pmid":"21191067","id":"PMC_21191067","title":"Cutting edge: NLRC5-dependent activation of the inflammasome.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21191067","citation_count":179,"is_preprint":false},{"pmid":"20061403","id":"PMC_20061403","title":"The nucleotide-binding oligomerization domain-like receptor NLRC5 is involved in IFN-dependent antiviral immune responses.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20061403","citation_count":173,"is_preprint":false},{"pmid":"20538593","id":"PMC_20538593","title":"A role for the human nucleotide-binding domain, leucine-rich repeat-containing family member NLRC5 in antiviral responses.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20538593","citation_count":145,"is_preprint":false},{"pmid":"38878777","id":"PMC_38878777","title":"NLRC5 senses NAD+ depletion, forming a PANoptosome and driving PANoptosis and inflammation.","date":"2024","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/38878777","citation_count":134,"is_preprint":false},{"pmid":"34782627","id":"PMC_34782627","title":"SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34782627","citation_count":134,"is_preprint":false},{"pmid":"22412192","id":"PMC_22412192","title":"NLRC5 deficiency selectively impairs MHC class I- dependent lymphocyte killing by cytotoxic T cells.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22412192","citation_count":134,"is_preprint":false},{"pmid":"23815151","id":"PMC_23815151","title":"Rhinovirus-induced calcium flux triggers NLRP3 and NLRC5 activation in bronchial cells.","date":"2013","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23815151","citation_count":125,"is_preprint":false},{"pmid":"22491475","id":"PMC_22491475","title":"NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens.","date":"2012","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/22491475","citation_count":124,"is_preprint":false},{"pmid":"22473004","id":"PMC_22473004","title":"Enhanced TLR-induced NF-κB signaling and type I interferon responses in NLRC5 deficient mice.","date":"2012","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/22473004","citation_count":116,"is_preprint":false},{"pmid":"21148033","id":"PMC_21148033","title":"NLRC5 deficiency does not influence cytokine induction by virus and bacteria infections.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21148033","citation_count":98,"is_preprint":false},{"pmid":"22711889","id":"PMC_22711889","title":"Cutting edge: impaired MHC class I expression in mice deficient for Nlrc5/class I transactivator.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22711889","citation_count":90,"is_preprint":false},{"pmid":"25811463","id":"PMC_25811463","title":"NLRC5 exclusively transactivates MHC class I and related genes through a distinctive SXY module.","date":"2015","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25811463","citation_count":79,"is_preprint":false},{"pmid":"28718425","id":"PMC_28718425","title":"NLRC5/CITA: A Key Player in Cancer Immune Surveillance.","date":"2017","source":"Trends in cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28718425","citation_count":73,"is_preprint":false},{"pmid":"22209772","id":"PMC_22209772","title":"NLRC5: a newly discovered MHC class I transactivator (CITA).","date":"2011","source":"Microbes and infection","url":"https://pubmed.ncbi.nlm.nih.gov/22209772","citation_count":73,"is_preprint":false},{"pmid":"26975630","id":"PMC_26975630","title":"NLRC5 regulates cell proliferation, migration and invasion in hepatocellular carcinoma by targeting the Wnt/β-catenin signaling pathway.","date":"2016","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/26975630","citation_count":72,"is_preprint":false},{"pmid":"27471621","id":"PMC_27471621","title":"NLRC5 elicits antitumor immunity by enhancing processing and presentation of tumor antigens to CD8(+) T lymphocytes.","date":"2016","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/27471621","citation_count":71,"is_preprint":false},{"pmid":"32355214","id":"PMC_32355214","title":"Transcriptional Upregulation of NLRC5 by Radiation Drives STING- and Interferon-Independent MHC-I Expression on Cancer Cells and T Cell Cytotoxicity.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32355214","citation_count":66,"is_preprint":false},{"pmid":"30872089","id":"PMC_30872089","title":"HIV-1 Tat-mediated microglial inflammation involves a novel miRNA-34a-NLRC5-NFκB signaling axis.","date":"2019","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/30872089","citation_count":62,"is_preprint":false},{"pmid":"28784305","id":"PMC_28784305","title":"Dexmedetomidine (DEX) protects against hepatic ischemia/reperfusion (I/R) injury by suppressing inflammation and oxidative stress in NLRC5 deficient mice.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28784305","citation_count":59,"is_preprint":false},{"pmid":"31207033","id":"PMC_31207033","title":"Knockdown of LncRNA SCAMP1 suppressed malignant biological behaviours of glioma cells via modulating miR-499a-5p/LMX1A/NLRC5 pathway.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31207033","citation_count":52,"is_preprint":false},{"pmid":"26620909","id":"PMC_26620909","title":"Reversible ubiquitination shapes NLRC5 function and modulates NF-κB activation switch.","date":"2015","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26620909","citation_count":51,"is_preprint":false},{"pmid":"29070585","id":"PMC_29070585","title":"NLRC5 deficiency ameliorates diabetic nephropathy through alleviating inflammation.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29070585","citation_count":51,"is_preprint":false},{"pmid":"25404059","id":"PMC_25404059","title":"NLRC5 interacts with RIG-I to induce a robust antiviral response against influenza virus infection.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25404059","citation_count":51,"is_preprint":false},{"pmid":"22310711","id":"PMC_22310711","title":"The nucleotide-binding domain of NLRC5 is critical for nuclear import and transactivation activity.","date":"2012","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/22310711","citation_count":50,"is_preprint":false},{"pmid":"26592197","id":"PMC_26592197","title":"NLRC5 regulates TGF-β1-induced proliferation and activation of hepatic stellate cells during hepatic fibrosis.","date":"2015","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26592197","citation_count":49,"is_preprint":false},{"pmid":"24319445","id":"PMC_24319445","title":"NLRC5, at the Heart of Antigen Presentation.","date":"2013","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24319445","citation_count":49,"is_preprint":false},{"pmid":"28432942","id":"PMC_28432942","title":"Insights into the diversity of NOD-like receptors: Identification and expression analysis of NLRC3, NLRC5 and NLRX1 in rainbow trout.","date":"2017","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28432942","citation_count":48,"is_preprint":false},{"pmid":"26861112","id":"PMC_26861112","title":"NLRC5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26861112","citation_count":47,"is_preprint":false},{"pmid":"30644097","id":"PMC_30644097","title":"Long noncoding RNA MEG3 regulates rheumatoid arthritis by targeting NLRC5.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30644097","citation_count":46,"is_preprint":false},{"pmid":"23483478","id":"PMC_23483478","title":"Expression regulation and function of NLRC5.","date":"2013","source":"Protein & cell","url":"https://pubmed.ncbi.nlm.nih.gov/23483478","citation_count":42,"is_preprint":false},{"pmid":"25972545","id":"PMC_25972545","title":"Respiratory Syncytial Virus Infection Upregulates NLRC5 and Major Histocompatibility Complex Class I Expression through RIG-I Induction in Airway Epithelial Cells.","date":"2015","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/25972545","citation_count":42,"is_preprint":false},{"pmid":"28499247","id":"PMC_28499247","title":"NLRC5 deficiency promotes myocardial damage induced by high fat diet in mice through activating TLR4/NF-κB.","date":"2017","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/28499247","citation_count":41,"is_preprint":false},{"pmid":"30706093","id":"PMC_30706093","title":"Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.","date":"2019","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/30706093","citation_count":40,"is_preprint":false},{"pmid":"32010261","id":"PMC_32010261","title":"LncRNA MALAT1 prevents the protective effects of miR-125b-5p against acute myocardial infarction through positive regulation of NLRC5.","date":"2019","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32010261","citation_count":40,"is_preprint":false},{"pmid":"30543814","id":"PMC_30543814","title":"NLRC5 mediates cell proliferation, migration, and invasion by regulating the Wnt/β-catenin signalling pathway in clear cell renal cell carcinoma.","date":"2018","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/30543814","citation_count":39,"is_preprint":false},{"pmid":"22024701","id":"PMC_22024701","title":"Regulation of immune pathways by the NOD-like receptor NLRC5.","date":"2011","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/22024701","citation_count":38,"is_preprint":false},{"pmid":"31434695","id":"PMC_31434695","title":"The deficiency of miR-214-3p exacerbates cardiac fibrosis via miR-214-3p/NLRC5 axis.","date":"2019","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/31434695","citation_count":38,"is_preprint":false},{"pmid":"32633419","id":"PMC_32633419","title":"MHC class I transactivator NLRC5 in host immunity, cancer and beyond.","date":"2020","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32633419","citation_count":36,"is_preprint":false},{"pmid":"33671123","id":"PMC_33671123","title":"The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33671123","citation_count":36,"is_preprint":false},{"pmid":"36103539","id":"PMC_36103539","title":"Transcription and splicing regulation by NLRC5 shape the interferon response in human pancreatic β cells.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/36103539","citation_count":35,"is_preprint":false},{"pmid":"30867141","id":"PMC_30867141","title":"NLRC5: A paradigm for NLRs in immunological and inflammatory reaction.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/30867141","citation_count":34,"is_preprint":false},{"pmid":"24445959","id":"PMC_24445959","title":"NLRC5 mediates cytokine secretion in RAW264.7 macrophages and modulated by the JAK2/STAT3 pathway.","date":"2014","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/24445959","citation_count":34,"is_preprint":false},{"pmid":"29692724","id":"PMC_29692724","title":"The Long Non-coding RNA MEG3/miR-let-7c-5p Axis Regulates Ethanol-Induced Hepatic Steatosis and Apoptosis by Targeting NLRC5.","date":"2018","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29692724","citation_count":34,"is_preprint":false},{"pmid":"34974132","id":"PMC_34974132","title":"LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer.","date":"2021","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/34974132","citation_count":33,"is_preprint":false},{"pmid":"22401171","id":"PMC_22401171","title":"NLRC5 knockdown in chicken macrophages alters response to LPS and poly (I:C) stimulation.","date":"2012","source":"BMC veterinary research","url":"https://pubmed.ncbi.nlm.nih.gov/22401171","citation_count":33,"is_preprint":false},{"pmid":"29907459","id":"PMC_29907459","title":"NLRC5 deficiency protects against acute kidney injury in mice by mediating carcinoembryonic antigen-related cell adhesion molecule 1 signaling.","date":"2018","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/29907459","citation_count":32,"is_preprint":false},{"pmid":"26806094","id":"PMC_26806094","title":"Role of NLRC5 in progression and reversal of hepatic fibrosis.","date":"2016","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26806094","citation_count":31,"is_preprint":false},{"pmid":"27338800","id":"PMC_27338800","title":"NLRC5 promotes cell proliferation via regulating the AKT/VEGF-A signaling pathway in hepatocellular carcinoma.","date":"2016","source":"Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/27338800","citation_count":31,"is_preprint":false},{"pmid":"34508321","id":"PMC_34508321","title":"MSCs-Derived Extracellular Vesicles Carrying miR-212-5p Alleviate Myocardial Infarction-Induced Cardiac Fibrosis via NLRC5/VEGF/TGF-β1/SMAD Axis.","date":"2021","source":"Journal of cardiovascular translational research","url":"https://pubmed.ncbi.nlm.nih.gov/34508321","citation_count":30,"is_preprint":false},{"pmid":"31824312","id":"PMC_31824312","title":"Emerging Roles for NLRC5 in Immune Diseases.","date":"2019","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31824312","citation_count":29,"is_preprint":false},{"pmid":"28865311","id":"PMC_28865311","title":"NLRC5 promotes cell proliferation via regulating the NF-κB signaling pathway in Rheumatoid arthritis.","date":"2017","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28865311","citation_count":29,"is_preprint":false},{"pmid":"32774715","id":"PMC_32774715","title":"The lncRNA XIST promotes the progression of breast cancer by sponging miR-125b-5p to modulate NLRC5.","date":"2020","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/32774715","citation_count":29,"is_preprint":false},{"pmid":"24815518","id":"PMC_24815518","title":"Unusual structural features revealed by the solution NMR structure of the NLRC5 caspase recruitment domain.","date":"2014","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24815518","citation_count":29,"is_preprint":false},{"pmid":"29655162","id":"PMC_29655162","title":"Knockdown of NLRC5 attenuates renal I/R injury in vitro through the activation of PI3K/Akt signaling pathway.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/29655162","citation_count":29,"is_preprint":false},{"pmid":"37072793","id":"PMC_37072793","title":"NOD-like receptor NLRC5 promotes neuroinflammation and inhibits neuronal survival in Parkinson's disease models.","date":"2023","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/37072793","citation_count":27,"is_preprint":false},{"pmid":"36126167","id":"PMC_36126167","title":"NLRC5 restricts dengue virus infection by promoting the autophagic degradation of viral NS3 through E3 ligase CUL2 (cullin 2).","date":"2022","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/36126167","citation_count":27,"is_preprint":false},{"pmid":"37085864","id":"PMC_37085864","title":"METTL3 facilitates immunosurveillance by inhibiting YTHDF2-mediated NLRC5 mRNA degradation in endometrial cancer.","date":"2023","source":"Biomarker research","url":"https://pubmed.ncbi.nlm.nih.gov/37085864","citation_count":26,"is_preprint":false},{"pmid":"34095138","id":"PMC_34095138","title":"The Regulatory NOD-Like Receptor NLRC5 Promotes Ganglion Cell Death in Ischemic Retinopathy by Inducing Microglial Pyroptosis.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34095138","citation_count":26,"is_preprint":false},{"pmid":"24044430","id":"PMC_24044430","title":"A molecular model of the full-length human NOD-like receptor family CARD domain containing 5 (NLRC5) protein.","date":"2013","source":"BMC bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/24044430","citation_count":26,"is_preprint":false},{"pmid":"29408916","id":"PMC_29408916","title":"Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancer.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29408916","citation_count":26,"is_preprint":false},{"pmid":"27525969","id":"PMC_27525969","title":"Silencing NLRC5 inhibits extracellular matrix expression in keloid fibroblasts via inhibition of transforming growth factor-β1/Smad signaling pathway.","date":"2016","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/27525969","citation_count":26,"is_preprint":false},{"pmid":"33547395","id":"PMC_33547395","title":"NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33547395","citation_count":26,"is_preprint":false},{"pmid":"30945291","id":"PMC_30945291","title":"NLRC5 negatively regulates LTA-induced inflammation via TLR2/NF-κB and participates in TLR2-mediated allergic airway inflammation.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30945291","citation_count":25,"is_preprint":false},{"pmid":"31186034","id":"PMC_31186034","title":"The expression of NOD2, NLRP3 and NLRC5 and renal injury in anti-neutrophil cytoplasmic antibody-associated vasculitis.","date":"2019","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31186034","citation_count":25,"is_preprint":false},{"pmid":"38424494","id":"PMC_38424494","title":"USF1 transcriptionally activates USP14 to drive atherosclerosis by promoting EndMT through NLRC5/Smad2/3 axis.","date":"2024","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/38424494","citation_count":24,"is_preprint":false},{"pmid":"27640334","id":"PMC_27640334","title":"Identification and expressional analysis of NLRC5 inflammasome gene in smolting Atlantic salmon (Salmo salar).","date":"2016","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27640334","citation_count":24,"is_preprint":false},{"pmid":"32431202","id":"PMC_32431202","title":"NLRC5 promotes cell migration and invasion by activating the PI3K/AKT signaling pathway in endometrial cancer.","date":"2020","source":"The Journal of international medical research","url":"https://pubmed.ncbi.nlm.nih.gov/32431202","citation_count":24,"is_preprint":false},{"pmid":"33364588","id":"PMC_33364588","title":"NLRC5 promotes transcription of BTN3A1-3 genes and Vγ9Vδ2 T cell-mediated killing.","date":"2020","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/33364588","citation_count":23,"is_preprint":false},{"pmid":"32710960","id":"PMC_32710960","title":"NLRC5 negatively regulates inflammatory responses in LPS-induced acute lung injury through NF-κB and p38 MAPK signal pathways.","date":"2020","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32710960","citation_count":23,"is_preprint":false},{"pmid":"31746301","id":"PMC_31746301","title":"miR-4319 Suppresses the Growth of Esophageal Squamous Cell Carcinoma Via Targeting NLRC5.","date":"2020","source":"Current molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31746301","citation_count":22,"is_preprint":false},{"pmid":"29608899","id":"PMC_29608899","title":"Knockdown of NLRC5 inhibits renal fibroblast activation via modulating TGF-β1/Smad signaling pathway.","date":"2018","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29608899","citation_count":22,"is_preprint":false},{"pmid":"22613950","id":"PMC_22613950","title":"NLRC5: a NOD-like receptor protein with many faces in immune regulation.","date":"2012","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/22613950","citation_count":22,"is_preprint":false},{"pmid":"33013364","id":"PMC_33013364","title":"NLRC5 Inhibits Inflammation of Secretory Phase Ectopic Endometrial Stromal Cells by Up-Regulating Autophagy in Ovarian Endometriosis.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33013364","citation_count":22,"is_preprint":false},{"pmid":"37325412","id":"PMC_37325412","title":"Macrophage-Specific NLRC5 Protects From Cardiac Remodeling Through Interaction With HSPA8.","date":"2023","source":"JACC. Basic to translational science","url":"https://pubmed.ncbi.nlm.nih.gov/37325412","citation_count":21,"is_preprint":false},{"pmid":"32169428","id":"PMC_32169428","title":"Innate Immune Molecule NLRC5 Protects Mice From Helicobacter-induced Formation of Gastric Lymphoid Tissue.","date":"2020","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/32169428","citation_count":21,"is_preprint":false},{"pmid":"27437103","id":"PMC_27437103","title":"NLRC5, a promising new entry in tumor immunology.","date":"2016","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27437103","citation_count":21,"is_preprint":false},{"pmid":"25820389","id":"PMC_25820389","title":"NLRC5 Mediates IL-6 and IL-1β Secretion in LX-2 Cells and Modulated by the NF-κB/Smad3 Pathway.","date":"2015","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/25820389","citation_count":21,"is_preprint":false},{"pmid":"32505342","id":"PMC_32505342","title":"NLRC5 deficiency ameliorates cardiac fibrosis in diabetic cardiomyopathy by regulating EndMT through Smad2/3 signaling pathway.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32505342","citation_count":20,"is_preprint":false},{"pmid":"27876605","id":"PMC_27876605","title":"Role of zebrafish NLRC5 in antiviral response and transcriptional regulation of MHC related genes.","date":"2016","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27876605","citation_count":20,"is_preprint":false},{"pmid":"28615208","id":"PMC_28615208","title":"Deficiency of the NOD-Like Receptor NLRC5 Results in Decreased CD8+ T Cell Function and Impaired Viral Clearance.","date":"2017","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/28615208","citation_count":20,"is_preprint":false},{"pmid":"31694750","id":"PMC_31694750","title":"Long noncoding RNA FER1L4 regulates rheumatoid arthritis via targeting NLRC5.","date":"2019","source":"Clinical and experimental rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/31694750","citation_count":19,"is_preprint":false},{"pmid":"36372300","id":"PMC_36372300","title":"USP14-mediated NLRC5 upregulation inhibits endothelial cell activation and inflammation in atherosclerosis.","date":"2022","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/36372300","citation_count":18,"is_preprint":false},{"pmid":"29394898","id":"PMC_29394898","title":"Methylation of the genes ROD1, NLRC5, and HKR1 is associated with aging in Hainan centenarians.","date":"2018","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/29394898","citation_count":18,"is_preprint":false},{"pmid":"31900803","id":"PMC_31900803","title":"Promotion on NLRC5 upregulating MHC-I expression by IFN-γ in MHC-I-deficient breast cancer cells.","date":"2019","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/31900803","citation_count":18,"is_preprint":false},{"pmid":"30559222","id":"PMC_30559222","title":"The Obligate Intracellular Bacterium Orientia tsutsugamushi Targets NLRC5 To Modulate the Major Histocompatibility Complex Class I Pathway.","date":"2019","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/30559222","citation_count":18,"is_preprint":false},{"pmid":"31925644","id":"PMC_31925644","title":"NLRC5: new cancer buster?","date":"2020","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/31925644","citation_count":17,"is_preprint":false},{"pmid":"32790491","id":"PMC_32790491","title":"NLRC5 alleviated OGD/R-induced PC12-cell injury by inhibiting activation of the TLR4/MyD88/NF-κB pathway.","date":"2020","source":"The Journal of international medical research","url":"https://pubmed.ncbi.nlm.nih.gov/32790491","citation_count":17,"is_preprint":false},{"pmid":"28713900","id":"PMC_28713900","title":"NLRC5 silencing ameliorates cardiac fibrosis by inhibiting the TGF‑β1/Smad3 signaling pathway.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28713900","citation_count":17,"is_preprint":false},{"pmid":"33090288","id":"PMC_33090288","title":"Arid2-IR promotes NF-κB-mediated renal inflammation by targeting NLRC5 transcription.","date":"2020","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/33090288","citation_count":17,"is_preprint":false},{"pmid":"35174769","id":"PMC_35174769","title":"Selective autophagy of NLRC5 promotes immune evasion of endometrial cancer.","date":"2022","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/35174769","citation_count":16,"is_preprint":false},{"pmid":"34536366","id":"PMC_34536366","title":"LncRNA MEG3 reverses CCl4-induced liver fibrosis by targeting NLRC5.","date":"2021","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34536366","citation_count":16,"is_preprint":false},{"pmid":"28122660","id":"PMC_28122660","title":"NLRC5 polymorphism is associated with susceptibility to chronic periodontitis.","date":"2017","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28122660","citation_count":16,"is_preprint":false},{"pmid":"33797607","id":"PMC_33797607","title":"NLRC5 regulates expression of MHC-I and provides a target for anti-tumor immunity in transmissible cancers.","date":"2021","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33797607","citation_count":15,"is_preprint":false},{"pmid":"32163856","id":"PMC_32163856","title":"Dexmedetomidine inhibits the invasion, migration, and inflammation of rheumatoid arthritis fibroblast-like synoviocytes by reducing the expression of NLRC5.","date":"2020","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32163856","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48597,"output_tokens":7042,"usd":0.125711},"stage2":{"model":"claude-opus-4-6","input_tokens":10862,"output_tokens":3822,"usd":0.22479},"total_usd":0.350501,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"NLRC5 inhibits NF-κB-dependent responses by directly interacting with IKKα and IKKβ and blocking their phosphorylation, and also interacts with RIG-I and MDA5 (but not MAVS) to inhibit RLR-mediated type I interferon responses.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown with NF-κB/IFN reporter assays, phosphorylation assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP plus functional knockdown phenotype, replicated in multiple cell types\",\n      \"pmids\": [\"20434986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NLRC5 is an IFN-γ-inducible nuclear protein that acts as a transcriptional regulator (class I transactivator, CITA) of MHC class I genes; it associates with MHC class I gene promoters and is required for IFN-γ-induced upregulation of MHC class I, β2-microglobulin, TAP1, and LMP2.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), reporter gene assays, siRNA knockdown, overexpression in lymphoid and epithelial cell lines\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus reporter assays plus KD phenotype, replicated across multiple studies\",\n      \"pmids\": [\"20639463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NLRC5 shuttles between the cytosol and the nucleus in a CrmA-dependent manner, and overexpression globally dampens NF-κB-, AP-1-, and type I IFN-dependent signaling, most likely through transcriptional repression.\",\n      \"method\": \"Subcellular fractionation/localization, overexpression in HEK293T cells, reporter assays, siRNA knockdown in RAW264.7 macrophages\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — localization with functional consequence shown, single lab\",\n      \"pmids\": [\"20610642\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NLRC5 forms an inflammasome complex: it biochemically associates with NLRP3 in a nucleotide-binding domain-dependent but LRR-inhibitory fashion, and together with procaspase-1, pro-IL-1β, and ASC reconstitutes inflammasome activity cooperative with NLRP3; RNAi knockdown nearly eliminated caspase-1, IL-1β, and IL-18 processing.\",\n      \"method\": \"Co-immunoprecipitation, reconstitution assay, siRNA knockdown in primary human monocytic cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biochemical reconstitution plus Co-IP, but later knockout studies showed partial or no confirmation\",\n      \"pmids\": [\"21191067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Overexpression and enforced oligomerization of NLRC5 activates IFN-γ activation sequence (GAS) and IFN-specific response element (ISRE) promoter elements and upregulates antiviral target genes; JAK/STAT-mediated autocrine IFN-γ signaling loop is involved in NLRC5 upregulation post-CMV infection.\",\n      \"method\": \"Reporter gene assays (GAS/ISRE), siRNA knockdown, overexpression with forced oligomerization\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — reporter assays with functional knockdown, single lab\",\n      \"pmids\": [\"20061403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NLRC5 deficiency in mice results in a profound defect specifically in MHC class I expression (and related genes β2M, TAP1, LMP2) in T, NKT, and NK lymphocytes but only mildly affects APCs; endogenous NLRC5 localizes to the nucleus and occupies proximal promoter regions of H-2 genes; MHC class I induction requires both CARD and LRR domains.\",\n      \"method\": \"Nlrc5-knockout mouse generation, flow cytometry, nuclear fractionation, ChIP\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in KO mice, replicated by independent labs\",\n      \"pmids\": [\"22412192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"In NLRC5-deficient mice, MHC class I expression and genes essential for antigen presentation (H-2K, H-2D, β2M, TAP1, LMP2) are severely reduced; IFN-γ stimulation cannot overcome this defect; Listeria-specific CD8+ T cell responses are impaired and bacterial clearance is reduced.\",\n      \"method\": \"NLRC5 knockout mouse, flow cytometry, bacterial infection model, CD8+ T cell functional assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — independent KO mouse study confirming MHC-I transactivation role with in vivo functional readout\",\n      \"pmids\": [\"22711889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NLRC5-deficient mice show enhanced IKK and IRF3 phosphorylation and increased IL-6 and IFN-β production in response to TLR stimulation or VSV infection; NLRC5 expression induction by TLR ligands or cytokines requires STAT1-mediated signaling.\",\n      \"method\": \"NLRC5 knockout mouse, phosphorylation assays (IKK, IRF3), ELISA for cytokines, STAT1 pathway analysis\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo KO mouse with multiple biochemical readouts\",\n      \"pmids\": [\"22473004\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NLRC5 is required for MHC class I-mediated antigen presentation in vivo; NLRC5-deficient mice show profound defect in MHC class I gene expression, fail to activate Listeria-specific CD8+ T cell responses, and show partial impairment of NLRP3-mediated inflammasome activation, but NLRC5 is dispensable for NF-κB-dependent pro-inflammatory gene expression and type I IFN genes.\",\n      \"method\": \"NLRC5 knockout mouse, flow cytometry, CD8+ T cell activation/proliferation/cytotoxicity assays, bacterial infection\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — independent KO mouse study with comprehensive in vivo analysis\",\n      \"pmids\": [\"22491475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The nucleotide-binding domain (NBD) of NLRC5 is critical for both nuclear translocation and transactivation of MHC class I genes; intact nuclear localization signal is required for NLRC5-mediated MHC class I gene induction.\",\n      \"method\": \"NBD domain mutants, nuclear localization signal mutagenesis, reporter gene assays, cellular localization studies\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — domain mutagenesis with functional reporter assays, single lab\",\n      \"pmids\": [\"22310711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The N-terminal effector domain of NLRC5 adopts a six α-helix bundle with a general death fold (atypical CARD), structurally distinct from canonical CARD; in vitro interaction experiments with the tandem CARD of RIG-I were performed; the atypical features affect the electrostatic surface and likely modulate CARD-CARD interactions.\",\n      \"method\": \"Solution NMR structure determination, in vitro pulldown/interaction experiments\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure with in vitro interaction validation\",\n      \"pmids\": [\"24815518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NLRC5 binds RIG-I via its N-terminal death domain; this interaction is critical for robust antiviral responses against influenza virus; NLRC5 extends and stabilizes influenza virus-induced RIG-I expression; influenza NS1 protein binds NLRC5 to suppress its function; antiviral activity is LRR domain-independent.\",\n      \"method\": \"Co-immunoprecipitation, domain mapping, overexpression/knockdown in A549 and primary bronchial cells, viral replication assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP with domain mapping, single lab\",\n      \"pmids\": [\"25404059\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NLRC5 exclusively transactivates MHC class I and related non-classical MHCI genes through an SXY enhancer module; recruitment of NLRC5 to MHC class I promoters absolutely requires the enhanceosome factor RFX5; NLRC5 and CIITA occupy distinct SXY motifs with the S box being the key determinant of NLRC5 specificity; Rfx5-knockout mice phenocopy Nlrc5 deficiency for MHCI expression.\",\n      \"method\": \"ChIP-sequencing, Rfx5-knockout mice, double-deficient Nlrc5/CIIta mice, de novo motif discovery, reporter assays in B cell lines lacking RFX5/RFXAP/RFXANK\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP-seq plus multiple KO mouse models plus reporter assays, comprehensive mechanistic study\",\n      \"pmids\": [\"25811463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NLRC5 undergoes K63-linked ubiquitination at lysine 1178 by TRAF2/6 after LPS treatment, which leads to dissociation of the NLRC5-IκB kinase complex and creates a coherent feedforward loop to sensitize NF-κB activation; USP14 specifically removes polyubiquitin chains from NLRC5 to restore NLRC5-mediated inhibition of NF-κB signaling.\",\n      \"method\": \"Ubiquitination assay, site-directed mutagenesis (K1178), Co-IP, mathematical modeling, USP14 deubiquitinase identification\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis identifying ubiquitination site, identification of writer (TRAF2/6) and eraser (USP14), plus mathematical modeling\",\n      \"pmids\": [\"26620909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NLRC5 shields T lymphocytes from NK-cell-mediated killing under inflammatory conditions by maintaining high MHCI expression; T-cell-specific Nlrc5-deficient mice show NK cells breaking tolerance toward self Nlrc5-deficient T cells under inflammation; during chronic LCMV infection, total CD8+ T cell population is severely decreased in a NK-cell-dependent manner.\",\n      \"method\": \"T-cell-specific Nlrc5-knockout mice, NK cell depletion, LCMV infection model, flow cytometry\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO mouse with NK depletion rescue, multiple orthogonal readouts\",\n      \"pmids\": [\"26861112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SARS-CoV-2 ORF6 protein suppresses NLRC5 both transcriptionally (by hampering IFN-γ-mediated STAT1 signaling, reducing NLRC5 and IRF1 gene expression) and functionally (by blocking karyopherin complex-dependent nuclear import of NLRC5), thereby inhibiting MHC class I pathway induction.\",\n      \"method\": \"Gene expression profiling of COVID-19 patients and infected cell lines, ORF6 overexpression, nuclear import assays, STAT1 signaling analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods identifying transcriptional and post-translational suppression mechanism with patient-derived data\",\n      \"pmids\": [\"34782627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NLRC5 promotes transcription of BTN3A1-3 genes through an atypical regulatory motif in their promoters; forcing NLRC5 expression promotes Vγ9Vδ2 T-cell-mediated killing of tumor cells in a BTN3A-dependent manner.\",\n      \"method\": \"ChIP, reporter assays, NLRC5 overexpression, co-culture killing assays with BTN3A neutralization\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus functional killing assay with BTN3A dependency shown, single lab\",\n      \"pmids\": [\"33364588\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NLRC5 interacts with dengue virus NS3 protease domain and mediates its degradation through a ubiquitin-dependent selective autophagy pathway; NLRC5 recruits E3 ubiquitin ligase CUL2 to catalyze K48-linked poly-ubiquitination of NS3, which serves as a recognition signal for TOLLIP-mediated selective autophagic degradation.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, autophagy pathway analysis, NLRC5 knockout/overexpression, viral replication assays\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus ubiquitination site identification plus autophagic degradation pathway, single lab\",\n      \"pmids\": [\"36126167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"NLRC5 acts as an innate immune sensor for NAD+ depletion and specific PAMP/heme and heme/cytokine combinations to drive PANoptosis (inflammatory cell death); NLRC5 interacts with NLRP12 and PANoptosome components to form a multi-protein cell death complex; TLR signaling and NAD+ levels regulate NLRC5 expression and ROS production to control cell death; NLRC5-deficient mice are protected in hemolytic and inflammatory models.\",\n      \"method\": \"PANoptosis screening, Co-immunoprecipitation with NLRP12 and PANoptosome components, NLRC5-deficient mice, cell death assays, ROS measurement\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP with multiple partners, KO mouse in vivo models, multiple orthogonal cell death readouts\",\n      \"pmids\": [\"38878777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In human pancreatic β cells, NLRC5 is induced by IFNα and regulates HLA class I expression, antigen presentation-related genes, chemokines, and mediates IFNα effects on alternative splicing that generates neoantigens.\",\n      \"method\": \"Bulk and single-cell RNA sequencing, NLRC5 knockdown in EndoC-βH1 and human islet cells, targeted gene/protein determination\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RNA-seq plus targeted KD with functional readouts, single lab\",\n      \"pmids\": [\"36103539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRMT5 inhibits transcription of the NLRC5 gene; PRMT5 knockdown augments NLRC5 expression and increases MHC class I abundance in melanoma cells; combining PRMT5 inhibition with immune checkpoint therapy enhanced antitumor efficacy.\",\n      \"method\": \"PRMT5 knockdown/inhibition, gene expression analysis, MHC-I flow cytometry, in vivo tumor models\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — functional KD with expression and in vivo readouts, PRMT5 identified as upstream transcriptional repressor\",\n      \"pmids\": [\"32641491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Autophagy protein LC3 directly interacts with NLRC5 and inhibits NLRC5-mediated MHC class I antigen presentation pathway in vitro and in vivo; negative correlation between NLRC5 and LC3 levels was found in endometrial cancer.\",\n      \"method\": \"Co-immunoprecipitation (LC3-NLRC5), overexpression/knockdown, in vivo tumor model, MHC-I expression assays\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP plus in vivo validation, single lab\",\n      \"pmids\": [\"34974132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"METTL3 facilitates m6A modification of NLRC5 mRNA; YTHDF2 promotes degradation of NLRC5 mRNA; METTL3 inhibits NLRC5 mRNA degradation through a YTHDF2-dependent mechanism, thereby promoting MHC-I-mediated immunosurveillance in endometrial cancer.\",\n      \"method\": \"RNA immunoprecipitation (RIP), methylated RIP, RNA stability assays, METTL3/YTHDF2 overexpression/depletion, in vivo tumor model\",\n      \"journal\": \"Biomarker research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RIP plus methylated RIP plus RNA stability assays identifying m6A writer and reader, single lab\",\n      \"pmids\": [\"37085864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"USP14 deubiquitinase directly interacts with NLRC5 and suppresses its degradation, thereby upregulating NLRC5-mediated inhibition of NF-κB signaling in endothelial cells to restrain atherosclerosis progression.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, USP14 overexpression/knockdown, in vivo ApoE-/- mouse model\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular and cell biology of lipids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP and functional KD/OE with in vivo model, single lab\",\n      \"pmids\": [\"36372300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"USP14 promotes deubiquitination and upregulation of NLRC5, with subsequent Smad2/3 pathway activation to drive endothelial-to-mesenchymal transformation (EndMT) in atherosclerosis; USF1 transcriptionally activates USP14, forming a USF1/USP14/NLRC5 axis.\",\n      \"method\": \"Dual-luciferase reporter assay, ChIP, Co-IP, USF1/USP14/NLRC5 knockdown/overexpression, in vivo ApoE-/- mouse model\",\n      \"journal\": \"Molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP, Co-IP, reporter assays, and in vivo confirmation, single lab\",\n      \"pmids\": [\"38424494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NLRC5 deficiency in macrophages decreases NF-κB pathway activation and reduces secretion of IL-6; mechanistically, NLRC5 interacts with HSPA8 (heat shock cognate protein 70) to suppress NF-κB signaling; myeloid-specific NLRC5 deletion aggravates pressure overload-induced cardiac remodeling.\",\n      \"method\": \"Myeloid-specific NLRC5 knockout mice, Co-immunoprecipitation (NLRC5-HSPA8), NF-κB signaling assays, cytokine measurement, cardiac remodeling model\",\n      \"journal\": \"JACC. Basic to translational science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO plus Co-IP identifying HSPA8 as binding partner, single lab\",\n      \"pmids\": [\"37325412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In HIV-1 Tat-exposed microglia, miRNA-34a is upregulated and directly targets NLRC5 mRNA (identified by bioinformatics and Argonaute immunoprecipitation); downregulation of NLRC5 by miR-34a leads to increased NF-κB p65 expression and microglial inflammation.\",\n      \"method\": \"Argonaute immunoprecipitation, miR-34a mimic/inhibitor transfection, NF-κB expression assays, validated in HIV-1 transgenic rat and SIV-infected macaque brain\",\n      \"journal\": \"Brain, behavior, and immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Argonaute IP plus in vivo validation in animal models, single lab\",\n      \"pmids\": [\"30872089\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NLRC5 deficiency in macrophages (myeloid-specific knockout) leads to higher chemokine and cytokine production in response to Helicobacter and promotes B-cell activating factor-driven B-cell hyperproliferation and gastric lymphoid tissue formation.\",\n      \"method\": \"Myeloid-specific Nlrc5-KO mice (Nlrc5mø-KO), CRISPR-Cas9 NLRC5-/- THP-1 cells, H. felis infection model, cytokine assays, histology\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO mouse plus CRISPR cell line with in vivo infection model, single lab\",\n      \"pmids\": [\"32169428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NLRC5 deficiency reduces dopaminergic neurodegeneration in MPTP-induced Parkinson's disease model; NLRC5 deficiency decreased proinflammatory gene expression in microglia and astrocytes by suppressing NF-κB and MAPK signaling pathways and enhancing AKT-GSK-3β and AMPK signaling; in neurons, NLRC5 deficiency promoted NF-κB and AKT signaling and increased survival.\",\n      \"method\": \"NLRC5-deficient mice, MPTP model, primary microglia/astrocyte cultures, NF-κB/MAPK/AKT signaling assays, dopaminergic neuron counting\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with multiple in vivo and in vitro mechanistic readouts, single lab\",\n      \"pmids\": [\"37072793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In ischemic retinopathy, NLRC5 directly binds NLRP3 and NLRC4 in inflammasomes to cooperatively drive microglial pyroptosis and apoptosis; NLRC5 knockdown markedly suppressed gasdermin D (GSDMD) cleavage and activation of IL-1β and caspase-3.\",\n      \"method\": \"Co-immunoprecipitation (NLRC5-NLRP3, NLRC5-NLRC4), NLRC5 knockdown in retinal microglia, GSDMD cleavage assay, retinal ischemia-reperfusion model\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP plus functional KD with defined pyroptosis readout, single lab\",\n      \"pmids\": [\"34095138\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NLRC5 is primarily established as the master transcriptional co-activator (CITA) of MHC class I genes, recruited to SXY enhancer motifs via the RFX5-containing enhanceosome complex where it drives coordinated expression of MHC-I, β2M, TAP1, and LMP2; it shuttles to the nucleus via a karyopherin-dependent mechanism requiring an intact NBD and NLS; it negatively regulates NF-κB signaling by interacting with and blocking phosphorylation of IKKα/β, with this inhibitory activity dynamically controlled by TRAF2/6-mediated K63-ubiquitination at K1178 and USP14-mediated deubiquitination; it also interacts with RIG-I and MDA5 to modulate antiviral interferon responses; and it can form PANoptosome cell death complexes with NLRP12 and inflammasome components to drive inflammatory cell death in response to NAD+ depletion and specific PAMPs.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"NLRC5 is a multifunctional NLR family member that serves as the master transcriptional co-activator (CITA) of MHC class I genes and modulates innate immune signaling and inflammatory cell death. NLRC5 is recruited to SXY enhancer motifs on MHC-I, β2-microglobulin, TAP1, LMP2, and BTN3A promoters through obligate interaction with the RFX5-containing enhanceosome complex, driving coordinated antigen presentation gene expression in an IFN-γ-inducible, karyopherin- and NBD/NLS-dependent manner [PMID:20639463, PMID:25811463, PMID:22412192, PMID:33364588]. In the cytoplasm, NLRC5 inhibits NF-κB signaling by directly binding IKKα/IKKβ and blocking their phosphorylation, with this inhibitory activity dynamically tuned by TRAF2/6-mediated K63-ubiquitination at K1178 and USP14-mediated deubiquitination [PMID:20434986, PMID:26620909, PMID:36372300]. NLRC5 also functions as an innate sensor of NAD+ depletion and specific PAMPs, assembling NLRP12-containing PANoptosome complexes to drive inflammatory cell death, and interacts with RIG-I via its atypical CARD to modulate antiviral interferon responses [PMID:38878777, PMID:20434986, PMID:25404059].\",\n  \"teleology\": [\n    {\n      \"year\": 2010,\n      \"claim\": \"The first functional characterization of NLRC5 established two cytoplasmic signaling roles — inhibition of NF-κB via direct IKKα/β binding and suppression of RLR-mediated type I IFN responses via RIG-I/MDA5 interaction — revealing it as a negative regulator of innate immune signaling.\",\n      \"evidence\": \"Co-immunoprecipitation, phosphorylation assays, and siRNA knockdown with reporter assays in multiple cell types\",\n      \"pmids\": [\"20434986\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for IKK interaction unknown\", \"Relative importance of NF-κB vs IFN inhibition in vivo not resolved\", \"Endogenous stoichiometry of NLRC5-IKK complex not measured\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Concurrent studies identified NLRC5 as a transcriptional co-activator (CITA) of MHC class I genes, fundamentally redefining NLRC5 from a purely cytoplasmic sensor to a nucleo-cytoplasmic shuttling transcriptional regulator that occupies MHC-I promoters and drives coordinated expression of antigen presentation machinery.\",\n      \"evidence\": \"ChIP on MHC-I promoters, reporter assays, siRNA knockdown, subcellular fractionation in lymphoid and epithelial lines\",\n      \"pmids\": [\"20639463\", \"20610642\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How NLRC5 is recruited to MHC-I promoters (cis-element specificity) not yet defined\", \"Whether NLRC5 acts independently or through co-factors unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Generation of NLRC5-knockout mice validated NLRC5 as the dominant, non-redundant transactivator of MHC class I in lymphocytes, showing that its loss profoundly impairs MHC-I expression, CD8+ T cell priming, and Listeria clearance, while its contribution to NF-κB and type I IFN suppression was confirmed by enhanced IKK/IRF3 phosphorylation in KO macrophages.\",\n      \"evidence\": \"Multiple independent NLRC5-KO mouse lines, flow cytometry, bacterial infection, CD8+ T cell assays, cytokine/phosphorylation measurements\",\n      \"pmids\": [\"22412192\", \"22711889\", \"22491475\", \"22473004\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Residual MHC-I expression in APCs implies compensatory mechanisms (likely CIITA) not fully delineated\", \"Whether NLRC5 inflammasome role is physiologically relevant was disputed by KO studies\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Domain mutagenesis established that the NBD is required for nuclear translocation and the NLS is essential for MHC-I transactivation, linking ATP-binding to the nuclear import mechanism.\",\n      \"evidence\": \"NBD and NLS mutants assessed by reporter assays and localization studies\",\n      \"pmids\": [\"22310711\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether NBD hydrolysis or just binding is required not distinguished\", \"Direct NLS–karyopherin interaction not biochemically mapped\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Structural determination of the NLRC5 N-terminal domain revealed an atypical CARD (six α-helix death fold) with a modified electrostatic surface, explaining how it engages RIG-I tandem CARDs and contributes to antiviral signaling.\",\n      \"evidence\": \"Solution NMR structure plus in vitro pulldown with RIG-I CARDs\",\n      \"pmids\": [\"24815518\", \"25404059\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length NLRC5 structure unavailable\", \"How atypical CARD engages enhanceosome or IKK not resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"ChIP-seq and genetic epistasis defined the mechanism of NLRC5 promoter specificity: NLRC5 is recruited exclusively to SXY enhancer modules via the RFX5 enhanceosome, with the S-box distinguishing NLRC5-dependent MHC-I from CIITA-dependent MHC-II promoters.\",\n      \"evidence\": \"ChIP-seq, Rfx5-KO and Nlrc5/CIIta double-KO mice, de novo motif analysis, reporter assays in RFX-deficient B cells\",\n      \"pmids\": [\"25811463\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise protein–protein contacts between NLRC5 and RFX5 not structurally resolved\", \"How atypical CARD contributes to enhanceosome assembly unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"A post-translational regulatory circuit was elucidated: TRAF2/6-mediated K63-ubiquitination at K1178 releases NLRC5 from IKK, creating a feedforward loop that sensitizes NF-κB, while USP14 deubiquitinates NLRC5 to restore inhibition — establishing dynamic control of NLRC5's NF-κB-suppressive function.\",\n      \"evidence\": \"Site-directed mutagenesis (K1178), ubiquitination assays, USP14 identification, mathematical modeling\",\n      \"pmids\": [\"26620909\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether K63-ubiquitination also affects nuclear import or MHC-I transactivation not tested\", \"Other E3 ligases or DUBs that regulate NLRC5 not excluded\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Conditional T-cell-specific NLRC5 deletion revealed the physiological consequence of NLRC5-driven MHC-I: protection of T cells from NK-cell-mediated killing during inflammation and chronic viral infection, establishing NLRC5 as essential for self-tolerance maintenance.\",\n      \"evidence\": \"T-cell-specific Nlrc5-KO mice, NK depletion rescue, LCMV infection model\",\n      \"pmids\": [\"26861112\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NK licensing is altered by NLRC5 deficiency not addressed\", \"Contribution of non-classical MHC-I ligands not separated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"The transcriptional target repertoire of NLRC5 was expanded beyond classical MHC-I to include BTN3A1-3 butyrophilin genes, linking NLRC5 to γδ T cell-mediated tumor surveillance, and upstream regulation by PRMT5-mediated transcriptional repression of NLRC5 itself was identified.\",\n      \"evidence\": \"ChIP and reporter assays for BTN3A promoters; PRMT5 knockdown/inhibition with MHC-I and tumor model readouts\",\n      \"pmids\": [\"33364588\", \"32641491\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether NLRC5 uses the same SXY/RFX5 mechanism for BTN3A not fully defined\", \"PRMT5 mechanism (direct histone methylation vs indirect) at NLRC5 locus not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"SARS-CoV-2 ORF6 was shown to suppress NLRC5 at two levels — blocking STAT1-dependent transcription of NLRC5 and inhibiting karyopherin-mediated nuclear import — revealing a viral immune evasion strategy targeting MHC-I transactivation.\",\n      \"evidence\": \"ORF6 overexpression, nuclear import assays, STAT1 signaling analysis, COVID-19 patient expression data\",\n      \"pmids\": [\"34782627\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other coronaviruses use the same mechanism unknown\", \"Impact on patient CD8+ T cell responses not directly measured\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Post-transcriptional regulation of NLRC5 was characterized: m6A modification of NLRC5 mRNA by METTL3 stabilizes it against YTHDF2-mediated decay, and LC3 directly binds NLRC5 protein to inhibit its MHC-I transactivation, adding epitranscriptomic and autophagic layers of control.\",\n      \"evidence\": \"RNA immunoprecipitation, methylated RIP, RNA stability assays, LC3-NLRC5 Co-IP with in vivo tumor models\",\n      \"pmids\": [\"37085864\", \"34974132\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether LC3 sequesters NLRC5 in the cytoplasm or promotes its degradation not distinguished\", \"m6A regulation in non-cancer contexts not examined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"A new cytoplasmic effector function was identified: NLRC5 recruits the E3 ligase CUL2 to catalyze K48-ubiquitination of dengue virus NS3, targeting it for TOLLIP-mediated selective autophagic degradation, linking NLRC5 to antiviral autophagy independent of its transcriptional role.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, autophagy pathway analysis, NLRC5 KO/OE with viral replication readouts\",\n      \"pmids\": [\"36126167\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether this autophagy-targeting function extends to other viral proteins unknown\", \"Structural basis for NS3 recognition not defined\", \"Single-lab finding awaits independent confirmation\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"NLRC5 was identified as an innate sensor of NAD+ depletion that assembles with NLRP12 and PANoptosome components to drive PANoptosis (combined pyroptosis, apoptosis, and necroptosis), establishing a cell death function distinct from its transcriptional and NF-κB-inhibitory roles.\",\n      \"evidence\": \"PANoptosis screening, Co-IP with NLRP12 and cell death effectors, NLRC5-KO mice in hemolytic and inflammatory models, ROS measurements\",\n      \"pmids\": [\"38878777\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How NLRC5 senses NAD+ depletion (direct binding vs indirect) not determined\", \"Structural basis of NLRC5-NLRP12 interaction unknown\", \"Whether PANoptosome function is active in non-myeloid cells not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major open questions include: (1) the structural basis for NLRC5 engagement with the RFX5 enhanceosome versus cytoplasmic signaling partners, (2) how the transcriptional, NF-κB-inhibitory, and PANoptosome functions are partitioned across cell types and stimuli, and (3) whether a unifying activation mechanism (nucleotide binding/hydrolysis) controls toggling between nuclear and cytoplasmic functions.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No full-length NLRC5 structure exists\", \"Relative contribution of each function in specific disease contexts not quantified\", \"Allosteric regulation by nucleotide binding/hydrolysis not mechanistically dissected\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 5, 6, 8, 12, 16, 19]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 7, 13, 23, 25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 2, 5, 9, 12]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 2, 13, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 5, 6, 7, 8, 11, 14, 15, 18]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 5, 12, 16, 19]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [18, 29]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [17]}\n    ],\n    \"complexes\": [\n      \"RFX5/RFXAP/RFXANK enhanceosome\",\n      \"NLRC5-NLRP12 PANoptosome\",\n      \"NLRC5-IKKα/β inhibitory complex\"\n    ],\n    \"partners\": [\n      \"RFX5\",\n      \"IKKα\",\n      \"IKKβ\",\n      \"NLRP12\",\n      \"RIG-I\",\n      \"USP14\",\n      \"TRAF2\",\n      \"HSPA8\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}